Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

Trial Details

NCT ID
NCT04879043
Phase
PHASE1 / PHASE2
Sponsor
Heidelberg Pharma AG
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • HDP-101
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • New York, New York, United States|40.71427,-74.00597
  • Houston, Texas, United States|29.76328,-95.36327
  • Berlin, Germany|52.52437,13.41053
  • Chemnitz, Germany|50.8357,12.92922

Key Eligibility Criteria

  • Male or female aged ≥18 years.
  • Life expectancy \>12 weeks.
  • Eastern Cooperative Oncology Group Performance Status (PS) of 0 to 2.
  • A confirmed diagnosis of active MM according to the diagnostic criteria established by the International Myeloma Working Group (IMWG).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →